FDA will wait for outcomes data regardless and likely review both at same time. These biomarker studies are overhyped for day traders. REGN earnings will drive to all-time high, that's real money not fantasy.
Roy Vagelos was the creative genius (ala Steve Jobs) who made Merck into the envy of the pharmaceutical world and Regeneron into the best biotech since Amgen. It would be a great strategic fit for Biogen to attempt a tax-free stock acquisition before the non-compete clause with Sanofi expires and Sanofi ruins the company. Otherwise a 3:1 stock split would be nice.
If there is any justice, a court will put a hold on the takeover for the blatant conflicts of interest and gross lack of fiduciary responsibility at every turn; You may not see that 125 for a while. The drumbeat of this case gets louder and louder. I will be glad to get back if the stock falls to 90.